Rituximab maintenance versus observation for untreated marginal zone lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares two approaches: continuing regular infusions of a drug called rituximab (a type of immunotherapy) versus simply watching and waiting, for people with a slow-growing lymphoma who cannot have chemo. Rituximab may help keep the lymphoma under control for a longer time, but it's not yet known which approach is better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed type of slow-growing lymphoma called marginal zone lymphoma.
- Your lymphoma cells have a protein called CD20 on them.
- You cannot receive or do not want standard chemotherapy.
- You have never had systemic treatment for your lymphoma (like chemo or immunotherapy).
- You have at least one lymphoma area that can be measured or seen on a scan, and your general health is fairly good.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) as the first treatment for marginal zone lymphoma that has spread or is advanced. The goal is to see if this combination is effective and safe for patients who have not had prior treatment.
This trial tests a combination of three drugs (orelabrutinib, zebetuzumab, and lenalidomide) for people newly diagnosed with a type of lymphoma called marginal zone lymphoma (MZL). If you qualify, you may receive this treatment to help control the disease.
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
This trial tests a combination of targeted drugs for people with a type of lymphoma called marginal zone lymphoma (MZL) that has not been treated before. The drugs attack cancer cells in different ways, and the treatment plan may adjust based on how you respond.
This trial tests a new combination of two drugs (orelabrutinib and rituximab) compared to the standard R-CVP chemotherapy for people with newly diagnosed marginal zone lymphoma. The goal is to see which approach works better and has fewer side effects.
This trial tests an oral medication called orelabrutinib as a follow-up treatment after initial therapy for marginal zone lymphoma that hasn't been treated yet. The goal is to see if it helps keep the lymphoma from coming back.
Hear when a new Marginal Zone Lymphoma(MZL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.